Patients with established MG and unexplained, recurrent thrombotic events despite anticoagulation, events in both the arterial and venous beds, or including the microcirculation with systemic manifestations with eminent end-organ damage, should prompt the clinician to consider a link between M-protein and the thrombotic manifestations. This evidence concerns the gene MYOM2 and myasthenia gravis.